# Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-congress-of-rheumatology-annual-meeting
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.fatetherapeutics.com
## Summary

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of rapid and sustained clinical improvement with favorable tolerability profile

## Article Body
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of rapid and sustained clinical improvement with favorable tolerability profile
## Recent Company News
- 2026-07-06 12:30 EST — [Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-ca-2ca1e01e) — Source: Fate Therapeutics
- 2026-07-01 20:05 EST — [Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences-457e2808) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Appoints Laura Hamill to Board of Directors](https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-congress-of-rheumatology-annual-meeting) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting) — Source: Fate Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)